U.S. markets closed

Pandion Therapeutics Holdco LLC (PAND)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.11+0.61 (+3.30%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close18.50
Bid18.90 x 900
Ask19.12 x 800
Day's Range18.25 - 19.47
52 Week Range16.67 - 27.75
Avg. Volume425,525
Market Cap545.128M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Barrons.com

      Qiagen, Pandion See Activist Actions

      Davidson Kempner Capital Management reported an 8% interest the Netherlands-based molecular testing firm Qiagen. Boxer Capital now owns 2,107,513 shares of newly public clinical-stage biopharmaceutical firm. Pandion Therapeutics.

    • MarketWatch

      Pandion Therapeutics stock shot up 50% at its open

      Pandion Therapeutics Inc. started its public life with a bang, as biotechnology company's stock opened 50% above where the upsized initial public offering was priced. The stock's first trade was at $27 at 11:59 a.m. Eastern for 252,125 shares, compared with the $18 IPO price, which was above the expected range. With about 27.99 million shares outstanding after the IPO, the opening price values the company at about $755.9 million. Pandion went public at a good time for IPOs, as the Renaissance IPO ETF has run up 44.9% over the past three months, while the S&P 500 has gained 12.1%.

    • MarketWatch

      Pandion Therapeutics' upsized IPO priced at the top of the expected range

      Pandion Therapeutics Inc. raised more than expected in its initial public offering, which was upsized to 7.5 million shares and priced at $18. The biotechnology company was previously planning to sell 7 million shares in the IPO, which was expected to price at $16 to $18 a share, to raise up to $126 million. With about 27.99 million shares outstanding after the IPO, the pricing values the company at $503.9 million. The stock is expected to begin trading Friday on the Nasdaq under the ticker symbol "PAND." Goldman Sachs, Morgan Stanley and SVB Leerink are acting as the joint bookrunning managers. The company is going public at a time that the Renaissance IPO ETF has rallied 44.6% over the past three months and the iShares Nasdaq Biotechnology ETF has gained 13.5%, while the S&P 500 has advanced 11.9%.